Sir, Faropenem is a novel oral β-lactam antimicrobial (no longer under development) for therapy of community-acquired respiratory tract and other infections. Previous studies have highlighted the broad spectrum of activity of this compound (also known as SUN/SY 5555, ALP-201 and WY-49605) against Gram-negative, Gram-positive and also anaerobic bacteria. In addition, faropenem MICs have been shown to be unaffected by β-lactamase production in common respiratory tract and other pathogens. [1] [2][3][4] In this study, broth microdilution and time-kill methodology were used to examine the in vitro activity of faropenem compared with a variety of antimicrobials against 14 Gramnegative and -positive pathogens, including four staphylococci, four streptococci and six Enterobacteriaceae. Faropenem was compared with levofloxacin, cefuroxime, co-amoxiclav and ceftriaxone (all strains); with linezolid and azithromycin (staphylococci and streptococci) and with linezolid, vancomycin and azithromycin (staphylococci).
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All organisms were recent cultures isolated from clinical specimens within the past year identified by standard methodology. All had faropenem MICs in the range described by other authors. 1 Time-kill activities were as described previously 6 using cation-adjusted Mueller-Hinton broth (Difco) + 5% lysed horse blood for streptococci. Antibiotic concentrations were chosen to comprise the MIC and two doubling dilutions above the MIC. Growth controls with inoculum but no antibiotic were included with each experiment. The original inoculum was determined using the untreated growth control. Only tubes containing an initial inoculum within the range of 5 × 10 5 to 5 × 10 6 cfu/mL were acceptable. 6 Viability counts of antibiotic-containing suspensions were carried out at 0, 3, 6, 12 and 24 h as described previously 6 using blood agar plates for all species except P. mirabilis where MacConkey agar was used to prevent swarming. Colony counts were carried out on plates yielding 30-300 colonies. The lower limit of sensitivity of colony counts was 300 cfu/mL. 6 Time-kill assays were analysed by determining the number of strains which yielded a ∆log 10 cfu/mL of -1, -2 and -3 at 3, 6, 12 and 24 h, compared with counts at 0 h. Antimicrobials were considered bactericidal at the lowest concentration that reduced the original inoculum by ≥3 log 10 cfu/mL (99.9%) at each of the time periods, and bacteriostatic if the inoculum was reduced by 0-<3 log 10 cfu/mL. The problem of bacterial carryover was addressed by dilution as described previously. 6 For levofloxacin, the one strain with levofloxacin MIC > 32.0 mg/L, and for azithromycin, the one strain with azithromycin MIC > 256.0 mg/L, were excluded from time-kill analysis.
Results of microdilution MICs are presented in Table 1 . As can be seen, faropenem MICs ranged between 0.03 and 8.0 mg/L with the highest MICs being found for Gramnegative bacteria especially P. mirabilis strains. Results of time-kill analyses (presented as log 10 reduction at the MIC after 24 h) are listed in Table 1 . Faropenem was bactericidal (99.9% killing) against 10 of the 14 strains tested at 2 × MIC and 13 of the 14 strains at 4 × MIC after 24 h. In comparison, levofloxacin, cefuroxime, co-amoxiclav and ceftriaxone were bactericidal against 6-11 strains at 2 × MIC after 24 h. One strain of S. saprophyticus with cefuroxime, and one strain of S. aureus with co-amoxiclav, had 99.9% killing at 4 × MIC after 12 h but showed regrowth at 24 h. Linezolid, vancomycin and azithromycin were predominantly bacteriostatic against Gram-positive organisms after 24 h (vancomycin was only tested against staphylococci).
Our results confirm findings by other authors. Lower MICs of faropenem as well as other β-lactams for Gram-positive compared with Gram-negative organisms have also been described before. [1] [2] [3] [4] Additionally, faropenem yielded favourable kill kinetics relative to the MIC against all organisms tested, compared with other β-lactams and levofloxacin. Vancomycin and linezolid, agents active against Gram-positive organisms only, were predominantly bacteriostatic.
Results of the current MIC and time-kill studies must be integrated with pharmacokinetic/pharmacodynamic findings before conclusions can be reached as to clinical validity. 
